Lung Function

Infants with a food allergy experience a greater risk for deficits in lung function and for asthma at age 6 years, according to a study published in The Lancet Child & Adolescent Health.

In healthy adults, higher levels of omega-3 fatty acids promoted lung health by lowering the rate of yearly lung function decline, according to results published in American Journal of Respiratory and Critical Care Medicine.

Among patients with pulmonary sarcoidosis, efzofitimod was safe through 24 weeks, and it improved measures of lung function and quality of life when given at a higher dosage, according to study results published in CHEST.

Emerging data suggest e-cigarettes and vaping products could increase risk for CV and pulmonary events and are not a “safe” alternative to combustible cigarettes, according to a new scientific statement from the American Heart Association.

Inhaled treprostinil was safe in patients with pulmonary hypertension associated with interstitial lung disease over 1 year and sustained improved exercise capacity, according to study results published in European Respiratory Journal.

An increase in exacerbations and worse lung function was found in those with advanced COPD and blood eosinophil counts less than or equal to 100 compared with those with higher counts, according to study results published in CHEST.

WASHINGTON — Among healthy young adults, 28% had intermediate sweat chloride levels, with lung function measures similar to those with normal levels, according to a poster presented at the American Thoracic Society International Conference.

WASHINGTON — By using race specific equations when interpreting pulmonary function tests, racism and bias come to the surface, according to a presentation at the American Thoracic Society International Conference.

Early-life TB was related to future wheezing, weak lung function and low measures of weight and height at 5 years old, according to study results published in American Journal of Respiratory and Critical Care Medicine.

WASHINGTON — At 52 weeks, adults with moderate/severe COPD and type 2 inflammation receiving dupilumab had a lower exacerbation rate and better lung function, according to an American Thoracic Society International Conference presentation.